The interim analysis results in phase III clinical study of TIGER (CML V) showed that the upfront accession of Peg-IFN to Nilotinib further increased MR4.0 and MR4.5 rates, which may translate into higher TFR rates (105). This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.